EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

National representative survey of pretreatment HIV drug resistance in Colombia: analysis of antiretroviral resistance-associated mutations using next-generation sequencing

Ernesto Martínez-Buitrago iD, Andrés Felipe Zapata-Marín, Luisa Consuelo Rubiano, Luz Marina Sañudo, José Millán Oñate, William Lenis, José Fernando García-Góez, Jorge Enrique Álvarez, Claudia García-Morales, Margarita Matías-Florentino, Santiago Ávila-Ríos

Journal of Antimicrobial Chemotherapy · 2026

DOI: 10.1093/jac/dkaf444 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Ernesto Martínez-Buitrago und 10 weiteren Autor:innen. Beteiligte Einrichtung: Fundación REVIVA, Red de VIH del Valle del Cauca, Cali, Colombia. Hauptthemen laut MEDLINE: HIV Infections, Drug Resistance, Viral, HIV-1, Mutation. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: ViiV Healthcare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

HIV pretreatment drug resistance (PDR) is an increasing global concern affecting transmitted resistance and first-line therapy effectiveness. Colombia lacks recent nationwide data on transmitted resistance. Although national guidelines recommend second-generation integrase strand transfer inhibitors (INSTIs) as preferred first-line options, efavirenz remains widely prescribed. This study estimated HIV PDR prevalence in Colombia to inform best practices for first-line antiretroviral therapy.

Methods

We conducted a cross-sectional, nationally representative survey using next-generation sequencing of plasma samples from individuals initiating or reinitiating first-line antiretroviral treatment across Colombia’s natural regions, stratified by national HIV prevalence data. Samples collected between 2021 and 2023 were analysed for drug resistance mutations (DRMs) following World Health Organization recommendations and interpreted using Stanford HIVdb v9.6.

Results

A total of 483 participants were enrolled; 98.3% had HIV-1 subtype B, 94.3% were Colombian nationals, the median age was 32.5 years (standard deviation ± 10.8), 19.9% were female, and 27.5% had CD4 counts <200 cells/mm³. Median HIV-1 RNA was 54 754 copies/mL (interquartile range [IQR]: 15 685–166 000); 6.2% were treatment reinitiators. The wild-type virus was identified in 61.7%. Overall, PDR prevalence was 20.3% (95% confidence interval [CI] 16.8–24.2), driven mainly by non-nucleoside reverse transcriptase inhibitor resistance (NNRTI) (18.0%, 95% CI 14.7–21.7), with K103N as the most frequent DRM. INSTI DRMs were rare (2.1%).

Conclusions

This nationwide survey demonstrates alarmingly high NNRTI resistance but minimal INSTI resistance, underscoring the urgent need to phase out efavirenz-based regimens. Strengthening access to affordable second-generation-based therapies and enhancing prescriber education are critical to sustaining treatment efficacy and preventing further transmission of resistant HIV strains.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsDrug Resistance, ViralHIV-1MutationAnti-HIV AgentsHumansColombiaCross-Sectional StudiesHigh-Throughput Nucleotide SequencingFemaleAdultMaleMiddle AgedPrevalenceYoung AdultAlkynesCyclopropanesBenzoxazines

Substanzen

Anti-HIV AgentsefavirenzAlkynesCyclopropanesBenzoxazines

Autor:innen und Institutionen

  • Fundación REVIVA, Red de VIH del Valle del Cauca, Cali, Colombia.
  • Department of Internal Medicine, Universidad del Valle, Cali, Colombia.
  • Corporación de Lucha Contra el SIDA, Cali, Colombia.
  • Fundación Casa GAMI, Cali, Colombia.
  • Clinica Imbanaco, Cali, Colombia.
  • Recuperar IPS, Cali, Colombia.

ORCID-Profile: Ernesto Martínez-Buitrago

Förderung

  • ViiV Healthcare

Zitieren

APA

Martínez-Buitrago, E., Zapata-Marín, A. F., Rubiano, L. C., Sañudo, L. M., Oñate, J. M., Lenis, W., García-Góez, J. F., Álvarez, J. E., García-Morales, C., Matías-Florentino, M., & Ávila-Ríos, S. (2026). National representative survey of pretreatment HIV drug resistance in Colombia: analysis of antiretroviral resistance-associated mutations using next-generation sequencing. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf444

Vancouver

Martínez-Buitrago E, Zapata-Marín AF, Rubiano LC, Sañudo LM, Oñate JM, Lenis W, et al. National representative survey of pretreatment HIV drug resistance in Colombia: analysis of antiretroviral resistance-associated mutations using next-generation sequencing. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkaf444

BibTeX
@article{MartnezBuitrago2026,
  author = {Martínez-Buitrago, Ernesto and Zapata-Marín, Andrés Felipe and Rubiano, Luisa Consuelo and Sañudo, Luz Marina and Oñate, José Millán and Lenis, William and García-Góez, José Fernando and Álvarez, Jorge Enrique and García-Morales, Claudia and Matías-Florentino, Margarita and Ávila-Ríos, Santiago},
  title = {National representative survey of pretreatment HIV drug resistance in Colombia: analysis of antiretroviral resistance-associated mutations using next-generation sequencing},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  doi = {10.1093/jac/dkaf444}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche